Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
With increasing overlap between advanced clear cell and non-clear cell RCC management with IO+TKI therapy, are there subtypes of non-clear cell RCC for which you would not use this approach?
Related Questions
How would you approach the use of bevacizumab in metastatic FH-deficient RCC/HLRCC that is c/b extensive IVC tumor thrombus and DVT/PE?
What perioperative systemic therapy would you use for a patient with oligometastatic clear cell RCC with a bony metastasis at risk for fracture?
Would you offer adjuvant immunotherapy in a patient with high risk RCC with new/worsening post-op renal dysfunction and CrCl<30?
What adjuvant therapy, if any, is best for mucinous tubular and spindle cell carcinoma of the kidney?
What are your top takeaways in GU Cancers from ESMO 2024?
How do you manage anemia associated with belzutifan therapy?
Is there still a role for mTOR inhibitors in metastatic RCC in the immunotherapy/TKI era?
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
Would the occurrence of obvious tumor rupture/spillage intraoperatively impact your decision for adjuvant systemic therapy after resection of either clear cell RCC or papillary RCC?
Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?
